Sulphasalazine fails to prevent development of mucosal ulceration and 5-lipoxygenase activity in guinea-pigs with chronic inflammatory bowel disease induced by combined bacterial immunization and oral carrageenin.
A model of inflammatory bowel disease in guinea-pigs involving a 14 day initial treatment with formalin-killed Bacteroides vulgatus subcutaneously and oral carrageenin plus live B. vulgatus for 10 days was used to determine the effects of sulphasalazine 100 mg kg-1 day-1 b.i.d., p.o. given for 4, 7 and 10 days after cessation of the bacterial/carrageenin treatment on the morphological and histological states of the established disease and on the production of the principal 5-lipoxygenase products, 5-hydroxyeicosatetraenoic acid and leukotriene B4. The drug treatment did not cause any significant changes in this established disease as measured by these parameters.
Department of Experimental Therapeutics, Wyeth Laboratories Inc, Philadelphia, PA 19101.
P
P
Oestreicher
S T
ST
Nielsen
K D
KD
Rainsford
D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D001439:Bacteroides / Q000276:immunology; D002351:Carrageenan; D006168:Guinea Pigs; D007114:Immunization; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D007413:Intestinal Mucosa / Q000201:enzymology / Q000473:pathology; D008297:Male; D012460:Sulfasalazine / Q000627:therapeutic use*; D014456:Ulcer / Q000517:prevention & control*
D012460:Sulfasalazine; D002351:Carrageenan; D001094:Arachidonate 5-Lipoxygenase